Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Average PT from Analysts

Carisma Therapeutics, Inc. (NASDAQ:CARM) has earned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $4.94.

A number of research analysts have issued reports on CARM shares. EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. Evercore ISI restated an “in-line” rating and set a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. D. Boral Capital reduced their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. Finally, BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th.

Carisma Therapeutics Stock Down 8.5 %

Shares of NASDAQ CARM opened at $0.47 on Monday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. Carisma Therapeutics has a 52 week low of $0.38 and a 52 week high of $2.94. The stock has a market capitalization of $19.79 million, a P/E ratio of -0.30 and a beta of 1.56. The stock’s fifty day moving average is $0.71 and its 200 day moving average is $0.94.

Carisma Therapeutics (NASDAQ:CARM) last released its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The firm had revenue of $3.39 million for the quarter. Sell-side analysts forecast that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Carisma Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics in the second quarter worth approximately $40,000. Wexford Capital LP lifted its stake in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Finally, Barclays PLC lifted its stake in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the period. 44.27% of the stock is owned by institutional investors and hedge funds.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.